Pyxis Oncology (PYXS) to Release Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is expected to be announcing its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.11 on Thursday. The stock has a 50-day moving average of $1.40 and a two-hundred day moving average of $2.48. Pyxis Oncology has a one year low of $0.99 and a one year high of $6.18. The stock has a market cap of $66.01 million, a P/E ratio of -1.08 and a beta of 1.12.

Institutional Trading of Pyxis Oncology

A hedge fund recently raised its stake in Pyxis Oncology stock. Bank of America Corp DE boosted its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,745 shares of the company’s stock after purchasing an additional 9,062 shares during the period. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 at the end of the most recent quarter. Institutional investors own 39.09% of the company’s stock.

Analyst Ratings Changes

PYXS has been the topic of several analyst reports. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.